As for TP53-knockdown, expression of TP53-V172F-protein increased basal drug-resistance, but impaired the FOXO3-imposed pro-survival phenotype (Figure 6c), proving that the disruption of FOXO3–TP53-complexes by this mutation abrogates the FOXO3-induced drug-protection in NB cells. This evidence concerns the gene TP53 and neuroblastoma.